Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Asset Writedowns and Impairment (2016)

Historic Asset Writedowns and Impairment for Tenax Therapeutics (TENX) over the last 5 years, with Q4 2016 value amounting to $33.3 million.

  • Tenax Therapeutics' Asset Writedowns and Impairment changed N/A to $33.3 million in Q4 2016 from the same period last year, while for Dec 2016 it was $34.9 million, marking a year-over-year increase of 130771.04%. This contributed to the annual value of $33.3 million for FY2016, which is N/A changed from last year.
  • As of Q4 2016, Tenax Therapeutics' Asset Writedowns and Impairment stood at $33.3 million.
  • In the past 5 years, Tenax Therapeutics' Asset Writedowns and Impairment ranged from a high of $33.3 million in Q4 2016 and a low of $763415.0 during Q1 2012
  • Moreover, its 4-year median value for Asset Writedowns and Impairment was $814791.0 (2012), whereas its average is $4.1 million.
  • As far as peak fluctuations go, Tenax Therapeutics' Asset Writedowns and Impairment skyrocketed by 16193.97% in 2012, and later soared by 300.35% in 2013.
  • Quarter analysis of 4 years shows Tenax Therapeutics' Asset Writedowns and Impairment stood at $802736.0 in 2012, then grew by 3.0% to $826846.0 in 2013, then changed by 0.0% to $826846.0 in 2014, then soared by 3923.13% to $33.3 million in 2016.
  • Its Asset Writedowns and Impairment was $33.3 million in Q4 2016, compared to $826846.0 in Q1 2014 and $826846.0 in Q4 2013.